BioSpace News Archive

GT Biopharma, Inc. (NASDAQ: GTBP), announced today that Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim CEO will be participating in a Fireside Chat at the upcoming B. Riley Securities’ Virtual Oncology Conference.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the Virtual Investor 2022 Top Picks Conference.

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), is pleased to announce it has received a written response from the U.S. Food and Drug Administration (FDA) to its pre-investigational new drug (pre-IND) application for the treatment of MDD with BETR-001.

IntelGenx Corp. today announced that patient dosing has resumed in the ongoing Phase 2a (“BUENA”) clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”) under a previously amended protocol using higher doses of Montelukast VersaFilm ® .

Akoya Biosciences, Inc., The Spatial Biology Company®, announced the appointment of Marilee Moy as Chief People Officer.

BioDelivery Sciences International, Inc. announced it expects 2021 total Company net revenues and BELBUCA® net sales to achieve the high end of its previous guidance range, and 2021 EBITDA to come in above its prior guidance range.

AVEO Oncology announced that new efficacy and safety data from the first line of the phase 1b/2 DEDUCTIVE study of FOTIVDA® in combination with IMFINZI® in previously untreated metastatic hepatocellular carcinoma are being presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

CalciMedica Inc. (CalciMedica or the Company), the CRAC (calcium release-activated calcium) channel company, today announced the initiation of CARDEA-Plus, a Phase 2b clinical trial being conducted in the United States and Canada, that may serve as a lead-in to its Phase 3 development program of Auxora™ in patients with critical COVID-19 pneumonia.

NanoDx, Inc., a privately held medical device company developing rapid, point-of-care diagnostic solutions that address unmet market needs and improve patient outcomes while reducing healthcare costs.

Blueprint Medicines Corporation today announced two executive leadership changes highlighting the company’s commitment to developing exceptional leaders.